Editas Medicine Stock News

The overall sell-off of biotech stocks appears to be the main culprit.

Editas Medicine is a gene-editing technology company. Editas Medicine has lost over 60% of its value.

Our theme of Gene Editing stocks remains down by about 11% year-to-date, considerably underperforming the S&P 500 which is up by a solid 23% over the same period. The theme would have actually decline

2021 wasn't the best year for gene-editing stocks, but expect a comeback in 2022. Here's the top gene-editing choice for next year.

Editas Medicine Inc. (NASDAQ:EDIT) has a beta value of 1.97 and has seen 1.38 million shares traded in the last trading session. The company, currently valued at $1.92B, closed the last trade at $30.20 per share which meant it gained $0.32 on the day or 1.07% during that session. The EDIT stock price is -230.96% … Why Should Editas Medicine Inc. (EDIT) Be In Your Portfolio? Read More »

HCR Wealth Advisors lowered its position in Editas Medicine, Inc. (NASDAQ:EDIT) by 6.2% in the third quarter, Holdings Channel reports. The fund owned 19,750 shares of the companys stock after selling 1,300 shares during the period. HCR Wealth Advisors holdings in Editas Medicine were worth $811,000 as of its most recent SEC filing. A number []

The CHMP gives a positive opinion on, and recommends approval to Seagen's (SGEN) Padcev as a monotherapy for treating adult patients with locally advanced/metastatic urothelial cancer.

The FDA approves Global Blood's (GBT) sNDA for Oxbryta to treat SCD in children aged four to less the 12 years, and NDA for a pediatric weight-based formulation of the drug.

EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia

Editas Medicine (NASDAQ:EDIT) and Protara Therapeutics (NASDAQ:TARA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Earnings & Valuation This table compares Editas Medicine and Protara Therapeutics gross revenue, earnings per share []

Editas Medicine, Inc. (NASDAQ:EDIT) reached a new 52-week low during mid-day trading on Friday . The company traded as low as $26.86 and last traded at $29.45, with a volume of 36349 shares changing hands. The stock had previously closed at $27.83. A number of research analysts recently issued reports on EDIT shares. Chardan Capital []

These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.

Regarding the trend, note that the strongest trend exists on the 100 day timeframe. The post Editas Medicine Inc (EDIT): Price Now Near $27.02; Daily Chart Shows Downtrend on 20 Day Basis appeared first on ETF Daily News .

The trading price of Editas Medicine Inc. (NASDAQ:EDIT) closed lower on Tuesday, December 14, closing at $28.62, -2.19% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy